If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4basebio Plc Regulatory News (4BB)

Share Price Information for 4basebio Plc (4BB)

Share Price is delayed by 15 minutes
Get Live Data
525.00    0.00 (0.00%)
Bid:
500.00
Ask:
550.00
Spread: 50.00 (10.00%)
Market Cap: £81.30m
4BB Live PriceLast checked at - London Stock Exchange

Intraday 4basebio Plc Share Chart

Holding(s) in Company

15 Nov 2024 07:00

4basebio Plc - Holding(s) in Company

4basebio Plc - Holding(s) in Company

PR Newswire

LONDON, United Kingdom, November 15

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: 4basebio PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: acting in concert under DTR 5.2.1(a) X
3. Details of person subject to the notification obligation iv
NameElevage Medical Technologies Holdings, LLC (as indirect parent shareholder under DTR 5.1.2 and 5.2.1(e) and indirect holder of voting rights under DTR 5.2.1(a))
City and country of registered office (if applicable)Wilmington, Delaware, United States
4. Full name of shareholder(s) (if different from 3.) v
NameFort Aggregator, LP (as direct shareholder) and the Prudential Assurance Company Limited (as the other party to the agreement under DTR5.2.1(a))
City and country of registered office (if applicable)Fort Aggregator, LP: Wilmington, Delaware, United States Prudential Assurance Company Limited: London, United Kingdom
5. Date on which the threshold was crossed or reached vi:13 November 2024
6. Date on which issuer notified (DD/MM/YYYY):14 November 2024
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached29.9029.94,627,741
Position of previous notification (if applicable)N/AN/AN/A
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct (DTR5.1)Indirect (DTR5.2.1)Direct (DTR5.1)Indirect (DTR5.2.1)
Ordinary shares of €1.00 each under DTR 5.2.1(e)ISIN: GB00BMCLYF7902,666,667017.2%
Ordinary shares of €1.00 each under DTR 5.2.1(a)ISIN: GB00BMCLYF791,961,0740 12.7%
SUBTOTAL 8. A4,627,74129.9%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/Conversion Period xiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/Conversion Period xiPhysical or cash Settlement xiiNumber of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Chain 1 in respect of Fort Aggregator LP:
Elevage Medical Technologies Holdings, LLC 17.2%17.2%
Elevage Medical Technologies GP, LLC 17.2%17.2%
Fort Aggregator, LP 17.2%17.2%
Chain 2 in respect of the Prudential Assurance Company Limited
M&G plc 12.7%12.7%
M&G Group Regulated Entity Holding Company Limited12.7%12.7%
M&G Group Limited12.7%12.7%
M&G FA Limited12.7%12.7%
M&G Investment Management Limited 12.7%12.7%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Fort Aggregator, LP and the Prudential Assurance Company Limited have concluded pursuant to DTR 5.2.1(a). As such, the disclosure in sections 7, 8 and 9 of this form reflects their aggregated position. A separate notification will be made on behalf of M&G plc in respect of the Prudential Assurance Company Limited’s shareholding.
Place of completionWilmington, Delaware, United States
Date of completion13 November 2024


Date   Source Headline
30th Jun 20265:37 pmPRNResult of AGM & Issue of Options
16th Jun 20267:00 amPRNNotice of Investor Presentation
15th Jun 20267:00 amPRN4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
5th Jun 20267:00 amPRNNotice of Annual General Meeting
22nd May 20269:10 amPRNDirector Dealing
20th May 20267:02 amPRNFinal Results and Notice of AGM
20th May 20267:00 amPRN4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
14th May 20267:00 amPRNAppointment of Chief Financial Officer and Board Changes
11th May 20267:00 amPRN4basebio Launches Enzymatic ssDNA Platform
31st Mar 20267:00 amPRNLease of Manufacturing Facility
12th Mar 20267:00 amPRNAppointment of COO
3rd Mar 20267:00 amPRNAppointment of CCO
16th Feb 20267:00 amPRNDirector Dealing
11th Feb 20263:58 pmPRNDirector Dealing
10th Feb 20267:00 amPRNLeadership Changes
27th Oct 20257:00 amPRNSynthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 202511:30 amPRNResult of Extraordinary General Meeting
30th Sep 20254:20 pmPRNDirector Dealing
29th Sep 20257:00 amPRNHalf-year Report
22nd Jul 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
8th Jul 202510:30 amPRNDirector Appointment, Board Change
3rd Jul 20257:00 amPRNHolding(s) in Company
3rd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
27th Jun 20256:05 pmPRNResult of AGM
25th Jun 20257:00 amPRNExercise of Options
17th Jun 20257:00 amPRNHolding(s) in Company
17th Jun 20257:00 amPRNHolding(s) in Company
27th May 20257:00 amPRNFinal Results and Notice of AGM
4th Apr 202512:00 pmPRNDirector Dealing
2nd Apr 20257:00 amPRN4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
25th Mar 202510:15 amPRNHolding(s) in Company
14th Mar 20257:00 amPRNRBC Capital Markets initiates research coverage
7th Mar 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
3rd Mar 20254:37 pmPRNDirector's Dealing
8th Jan 20257:00 amPRNAppointment of Chief Commercial Officer
17th Dec 20247:00 amPRNDirectorate Change
29th Nov 202412:30 pmPRNDirector's Dealing
19th Nov 20242:15 pmPRNDirector's Dealing
15th Nov 20245:31 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.